Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
Reads0
Chats0
TLDR
In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).Abstract:
In lifetesting, medical follow-up, and other fields the observation of the time of occurrence of the event of interest (called a death) may be prevented for some of the items of the sample by the previous occurrence of some other event (called a loss). Losses may be either accidental or controlled, the latter resulting from a decision to terminate certain observations. In either case it is usually assumed in this paper that the lifetime (age at death) is independent of the potential loss time; in practice this assumption deserves careful scrutiny. Despite the resulting incompleteness of the data, it is desired to estimate the proportion P(t) of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t). The observation for each item of a suitable initial event, marking the beginning of its lifetime, is presupposed. For random samples of size N the product-limit (PL) estimate can be defined as follows: L...read more
Citations
More filters
Journal ArticleDOI
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Winnie Yeo,Tony Mok,Benny Zee,Thomas W.T. Leung,Paul B.S. Lai,Wan Y. Lau,Jane Koh,Frankie Mo,Simon C.H. Yu,Anthony T.C. Chan,Pun Hui,Brigette B.Y. Ma,Kwok Chi Lam,Wing M. Ho,Herman T. Wong,Amanda Tang,Philip J. Johnson +16 more
TL;DR: Although patients on PIAF had a higher overall response rate and better survival than patients on doxorubicin, the differences were not statistically significant and the prognosis of patients with unresectable HCC remains poor.
Journal ArticleDOI
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
V. Trillet-Lenoir,John Green,Christian Manegold,J. von Pawel,U. Gatzemeier,Bernard Lebeau,Alain Depierre,Peter Johnson,G. Decoster,D. Tomita,C. Ewen +10 more
TL;DR: In this article, the usefulness of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) following conventional chemotherapy for small cell lung cancer was evaluated.
Journal ArticleDOI
Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.
TL;DR: The findings indicate that oral anticoagulants should be given to all patients with thrombi that produce symptoms and that treatment for 3 months seems to be sufficient.
Journal ArticleDOI
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome
TL;DR: Tumor oxygenation affects the prognosis of head and neck cancer independently of other known prognostic variables and this parameter may be a useful tool for the selection of patients for investigational treatment strategies.
Journal ArticleDOI
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra,Greg Yothers,Michael J. O'Connell,Saima Sharif,Nicholas J. Petrelli,Linda H. Colangelo,James N. Atkins,Thomas E. Seay,Louis Fehrenbacher,Richard M. Goldberg,Seamus O'Reilly,Luis Chu,Catherine A. Azar,Samia H. Lopa,Norman Wolmark +14 more
TL;DR: Bvacizumab for 1 year with mFOLFOX6 does not significantly prolong DFS in stages II and III colon cancer, and the use of bevacIZumab cannot be recommended for use in the adjuvant treatment of patients with colon cancer.
References
More filters
Journal ArticleDOI
Survival Curve for Cancer Patients Following Treatment
Joseph Berkson,Robert P. Gage +1 more
TL;DR: A simple function, in terms of two physically meaningful parameters, has been evolved, which fits survivorship data very well and can be used to compare succinctly the mortality of two groups, different in respect of treatment, type of cancer, or other characteristics.
Journal ArticleDOI
An analysis of some failure data
TL;DR: The rationale and statistical techniques employed in the analysis of some failure data obtained from operations performed by machines and people are summarized and the agreement between theory and data is evaluated.